Hims & Hers Health (NYSE:HIMS) Releases Earnings Results, Beats Estimates By $0.26 EPS

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings data on Monday. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26, Briefing.com reports. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Stock Performance

NYSE HIMS traded up $2.80 during trading hours on Wednesday, hitting $23.44. 36,916,662 shares of the company’s stock were exchanged, compared to its average volume of 8,618,266. The business’s 50 day moving average is $18.22 and its 200-day moving average is $18.26. Hims & Hers Health has a 12-month low of $6.58 and a 12-month high of $25.74. The firm has a market capitalization of $5.03 billion, a P/E ratio of 53.27 and a beta of 1.06.

Analyst Ratings Changes

HIMS has been the topic of a number of recent analyst reports. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. TD Cowen upped their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Bank of America upped their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial upped their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,339 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the transaction, the insider now directly owns 169,935 shares in the company, valued at approximately $3,935,694.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares in the company, valued at approximately $3,935,694.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 650,659 shares of company stock worth $11,712,198. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.